At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 10 enrolled

Drug / intervention

Suramin +1 moredrug

Likely dose

Suramin 20 mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02508259

NCT02508259Phase 2Completed

The UCSD Suramin Autism Treatment-1 (SAT1) Trial

University of California, San Diego·interventional·Posted Jul 24, 2015·Updated Jul 16, 2019

In Brief

A Phase 2 clinical trial evaluating Suramin and Saline for Autism Spectrum Disorders. Completed, enrolled 10 participants across 1 site.

This study is designed to test the safety and efficacy of a single, intravenous dose of suramin in autism spectrum disorders (ASD).

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesUnited States

Collaborators--

Phase 2CompletedFinished

20162017201820192020202120222023202420252026

Enrollment StartMay 2015

First PostedJul 2015

Primary CompletionMar 2016

Study CompletionApr 2016

TodayJul 2026

First PostedJul 24, 2015

Enrollment StartMay 1, 2015

Primary CompletionMar 1, 2016

Study CompletionApr 1, 2016

TodayJul 2, 2026

Enrollment to primary: 10 monthsPosted 10.9 years ago

Suramindrug

20 mg/kg IV in 50 ml saline over 30 minutes

Salinedrug

50 ml IV over 30 minutes